drugset / Trial / NCT02799082

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

NCT02799082

Phase 3 Completed 122 enrolled Biofrontera Bioscience GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study was to evaluate the efficacy and safety of BF-200 ALA (Ameluz) used with photodynamic therapy (PDT) in patients suffering from actinic keratosis.

Timeline

Start
2007-12
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aminolevulinic Acid Diagnostic / imaging agent 78 unknown Topical

Indications